IAI CONFERENCE: The therapeutic outcomes and adverse drug reactions study of Clozapine on Schizophrenia inpatients in the Grhasia psychiatric hospital Yogyakarta, Indonesia
DOI:
https://doi.org/10.46542/pe.2021.212.287295Keywords:
Adverse drug reaction, Clozapine, Schizophrenia, Therapeutic outcomeAbstract
Introduction: Clozapine is an antipsychotic agent used in schizophrenia recurrence or when other antipsychotics are not effective.
Aims: This study aims to determine the therapeutic outcome and adverse drug reactions of clozapine in schizophrenia disorder among hospitalised patients.
Methods: A retrospective cross-sectional study was conducted between January 2018 and December 2019 using inpatients’ medical records from the Grhasia Psychiatric Hospital, Yogyakarta. The therapeutic outcome was measured with the PANSS-EC scale, while adverse drug reactions of clozapine were analysed theoretically as per the literature.
Results: The average decrease in the PANSS-EC score was 8.27, and the average duration to achieve this decrease was 2.5 days. The combination of typical-atypical antipsychotics could reduce the highest PANSS-EC score of 11-15 (41%). The adverse drug reactions of clozapine were tremor, weight gain, obesity, leucopenia, hyperglycemia, and hypercholesterolemia, among other effects.
Conclusion: Clozapine is effective in improving positive and negative symptoms, but its use needs close monitoring.
References
Andreasen, N.C., & Black, D. W., (2006), Introductory Textbook of Psychiatry, USA: American Psychiatric Association Publishing
Aryani, F., & Sari, O., (2016), Gambaran Pola Penggunaan Antipsikotik Pada PasienSkizofrenia Di Ruang Rawat Inap Rumah Sakit Jiwa, Jurnal Manajemen dan Pelayanan Farmasi, 6 (1), 35-40. https://doi.org/10.22146/jmpf.236
Alldredge, B.K., Affairs, A., Francisco, S., Francisco, S., Corelli, R.L., Francisco, S., Francisco, S., Ernst, M.E., City, I., Guglielmo, B.J., Francisco, S., Francisco, S., Jacobson, P.A., Pharmacology, C., Kradjan, W.A., Emeritus, D., Health, O., Williams, B.R., Gerontology, C &Economics, P.,(10th Ed). (2013), Applied therapeutics: The clinical use of drugs, Philadelphia: Lippincott Williams & Wilkins
AphA., (21th Ed). (2019), Drug Information Handbook, Ohio: Lexicomp
Buchanan. R.W., Kreyenbuhl, J., Kelly, D.L., Noel, J.M., Boggs, D.L., & Fischer, B.A., (2010), The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin, 36, 71-93
Crismon, M.L., Argo, T.R., & Buckley, P.F., (9th Ed). (2015), Schizophrenia, Pharmacotherapy Handbook, USA: McGraw Hill Company
Dayabandara, M., Hanwella, R., Ratnatunga, S., Seneviratne, S., Suraweera, C. & de Silva, V.A, (2017), Antipsychotic-associated weight gain : management strategies and impact on treatment adherence, Neuropsychiatric Disease and Treatment, 2231–2241
De Luca, V., Mueller, D.J., de Bartolomeis, A. & Kennedy, J.L, (2007), Association of the HTR2C gene and antipsychotic-induced weight gain: a meta-analysis, International Journal Neuropsychopharmacol, 10: 697–704
Dipiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., & Posey, L.M., (9 th Ed). (2017), Pharmacotherapy: a pathophysiologic approach, New York: Mc Graw-Hill Medical Publishing Division
De Berardis, D., Gabriella, R., & Olivieri, L., (2018), Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine, Therapeutic Advances in Drug Safety, 9(6): 237–256
Divac, N., Prostran, M., Jakovcevski, I. & Cerovac, N, (2014), Extrapyramidal Adverse Effects, Biomed Res Int. https://doi.org/10.1155/2014/656370
Drake, E.R., (2018), Employment and Schizophrenia: Three Innovative Research Approaches, Schizophrenia Bulletin, 44 (1), https://doi.org/10.1093/schbul/sbx170
Durand, V.M., & Barlow, D.H., (4th Ed). (2007), Intisari Psikologi Abnormal, Yogyakarta: Terjemahan Pustaka Pelajar
Fahrul, F., Mukaddas, A., & Faustine, I., (2014), Rasionalitas Penggunaan Antipsikotik pada Pasien Skizofrenia di Instalasi Rawat Inap Jiwa RSD Madani Provinsi Sulawesi Tengah Periode Januari-April 2014, Online Journal of Natural Science, 3 (2), 18-29. Available at: http://jurnal.untad.ac.id/jurnal/index.php/ejurnalfmipa/article/view/2981
Gemilang, B.M., Lesmana, C.B.J., & Aryani, L.N.A., (2017), Karakteristik Pasien Relapse pada Pasien Skizofreniadan Faktor Pencetusnya di Rumah Sakit Jiwa (RSJ)Provinsi Bali, E-Jurnal Medika, 6 (10), 61-65. Available at: http://ojs.unud.ac.id/index.php/eum
Hariyanto, I., Putri, R.A., & Untari, E.K., (2016), Perbedaan Jenis Terapi Antipsikotik terhadap Lama Rawat Inap PasienSkizofrenia Fase Akut di RSJD Sungai Bangkong Pontianak, Jurnal Farmasi Klinik Indonesia, 5 (2), 115-122. https://doi.org/10.15416/ijcp.2016.5.2.115
Ikawati, Z., (2014), Farmakoterapi Sistem Saraf Pusat, Yogyakarta: Bursa Ilmu
Indriani, A., Ardiningrum, W., & Febrianti, Y., (2019), Studi Penggunaan Kombinasi Antipsikotik pada Pasien Skizofrenia di Rumah Sakit Yogyakarta, Majalah Farmasetika, 4(1), 201-211. https://doi.org/10.24198/mfarmasetika.v4i0.25882
Iqbal, M.M., Rahman, A., Husain, Z., Mahmud, S.Z., Ryan, W.G. & Feldman, J.M, (2003), Clozapine : A Clinical Review of Adverse Effects, Ann Clin Psychiatry,15(1): 33-48. https://doi.org/10.1023/a:1023228626309
Juleha, J., Athiyah, U., & Hermansyah A., (2019), The prescription patterns of second-generation antipsychotics in schizophrenia outpatient setting, Journal of Basic and Clinical Physiology and Pharmacology. https://doi.org/10.1515/jbcpp-2019-0289
Kay, S.R., Fiszbein, A., & Opler, L.A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276
Kay, S.R., & Singh, M.M., (1989). The Positive & Negative Distinction in drug free schizophrenia patients, Arch Gen Psychiatry, 46 (8), p 711–718
Liu, X., Wu, Z., Lian, J., Hu, C.H., Huang, X.F. & Deng, C. (2017). Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in rats, Scientific Reports, 7(1): 1–13
Meyler, L., (16th Ed). (2016), Meyler’s Side Effects of Drugs, Oxford, UK: Elsevier
Montoya A, Valladares A, Lizan L, San L, Escobar R, & Pan S, (2011). Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a Naturalistic Psychosis and Agitation in a Psychiatric Emergency Room. Health Qual Life Outcomes, 29 (9). 18. https://doi.org/10.1186/1477-7525-9-18
Ochoa, S., Usall, J., Cobo, J., Labad, X., & Kulkarni, J. (2012). Gender Differences in Schizophrenia and First-Episode Psychosis: A Comprehensive Literature Review, Schizophrenia Research and Treatment
Patel, K.R., Cherian, J., Gohil, K., & Atkinson, D., (2014), Schizophrenia: Overview and Treatment Options, Journal of Pharmacy & Therapeutics. 39 (9), 638–645
Pharmaceutical Services Programme. (2018). Adverse Drug Reactions of Clozapine and Their Management in a Tertiary Care Hospital in Kelantan, Pharmacy Research Reports, 1, Ministry of Health Malaysia
Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C.A., Kissling, W., Davis, J.M. & Leucht, S. (2010). Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. Schizophrenia Research, 123(2–3): 225–233
Sadock, B.J., Ahmad, S., & Sadock, V.A., (6th Ed). (2014), Kaplan & Sadock’s Pocket Handbook of Psychiatric Drug Treatment, USA: Lippincott William & Wilkins
Sharafi, M. (2005). Comparison of Classical and Clozapine Treatment on Schizophrenia Using Positive and Negative Syndrome Scale of Schizophrenia (PANSS) and SPECT Imaging. International Journal of Medical Sciences, 2(2):79-86
Sicard, M.., Zai, C.C., Tiwari, A.K., Souza, R.., Meltzer, H.Y., Lieberman, D.J., Kennedy, J.L. & Muller, D.J. (2010). Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain : an update and meta-analysis. Pharmacogenomics, 11: 1561–1571
Vancampfort, D., Sweers, K., Winkel, R. Van, Yu, W. & Hert, M. De. (2013). Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders. A Systematic Review and Meta-Analysis, 39(2): 306–318
Ventriglio, A., Baldessarini, R.J., Vitrani, G., Bonfitto, I., Cecere, A.C., Rinaldi, A., Petito, A. & Bellomo, A,. (2019), Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics
Yuen, J.W.Y., Kim, D.D., Procyshyn, R.M., White, R.F., Honer, W.G., & Barr, A. M.. (2018). Clozapine-Induced Cardiovascular Side Effect and Autonomic Dysfunction. A Systematic Review, Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2018.00203
